High Quality Peptide Pentadecapeptide Bpc 157

1.Basic info.

Product Name:Pentadecapeptide BPC 157

Alias:Booly Protection Compound 15

CAS NO.:137525-51-0

MF: C62H98N16O22 

MW: 1419.53552 

Purity: 99% 

Specification: 2mg/vial 

Appearance: White Lyophilized Powder 

2.Product description: 

BPC 157 has a strong anti-inflammatory activity in both acute and chronic inflammation models. In fact, preliminary results in clinical trials suggest that BPC 157 may become an important therapeutic tool for the treatment of inflammatory bowel disease. BPC 157 was shown to accelerate wound healing and to have a marked angiogenic effect. In addition, it significantly facilitates the healing of bone fracture in rats. This peptide also exhibits an osteogenic effect significantly improving the healing of segmental bone defect. BPC 157 accelerates the healing of transected rat Achilles tendon and transected rat quadriceps muscle.

FITC-phalloidin staining was able to demonstrate that BPC 157 induces F-actin formation in fibroblasts. Likewise, Western blot analysis was able to detect the production and activation of paxillin and FAK proteins. The western blot analysis also showed that BPC 157 increases the extent of phosphorylation of paxillin and FAK proteins without affecting the amounts produced.

3.Application: 

Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-saystem, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.

Keywords:BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II